Spark Therapeutics has already revolutionised treatment of a rare hereditary eye disease with a gene therapy, but could it be about to do the same with haemophilia B?
UCB is changing the way it conducts some of its research studies, removing the need for patients to attend hospitals by allowing them to take part in virtual clinical trials at home.